Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9UKU6

UPID:
TRHDE_HUMAN

ALTERNATIVE NAMES:
Pyroglutamyl-peptidase II; TRH-specific aminopeptidase; Thyroliberinase

ALTERNATIVE UPACC:
Q9UKU6; A5PL19; Q6UWJ4

BACKGROUND:
Thyrotropin-releasing hormone-degrading ectoenzyme, known alternatively as Pyroglutamyl-peptidase II, TRH-specific aminopeptidase, and Thyroliberinase, is pivotal for the inactivation of TRH post-release. It is identified by the unique identifier Q9UKU6.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionality of the Thyrotropin-releasing hormone-degrading ectoenzyme offers a promising avenue for the development of novel therapeutic interventions. Its key role in the deactivation of TRH highlights its potential impact on thyroid function and overall endocrine system health.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.